Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Zymeworks Inc (Zymeworks) is a biopharmaceutical company that discovers, develops and commercializes biotherapeutics for the treatment of cancer, autoimmune and inflammatory diseases. It is investigating its lead product candidate Zanidatamab for biliary tract, gastroesophageal adenocarcinomas, breast, and other HER2-expressing cancers; and ZW49, a HER2-targeted antibody drug conjugate (ADC) against advanced or metastatic HER2-expressing cancers. The company is also evaluating ADC’s, bispecifics, microenvironment and cytokine receptor modulators to treat solid tumors, infectious diseases, dermatology, oncology and immune-oncology indications. Zymeworks utilizes its proprietary Azymetric, Zymelink, Efect, and Protect technology platforms to discover and develop its products. The company operates a research and development site in Seattle, Washington, the US. Zymeworks is headquartered in Vancouver, British Columbia, Canada.

Headquarters Canada

Address 540-1385 West 8th Avenue, Vancouver, British Columbia, V6H3V9


Telephone 1 604 6781388

No of Employees 327

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange ZYME (NYSE)

Revenue (2021) $26.7M -31.5% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -17.3% (2021 vs 2020)

Market Cap* $353.6M

Net Profit Margin (2021) XXX -71.3% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Zymeworks Inc’s relevant decision makers and contact details.

40+

Pipeline Drugs

Identify which of Zymeworks Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Catalyst Calendar

Proactively evaluate Zymeworks Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

19+

Clinical Trials

Determine Zymeworks Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

5

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products
Pipeline
Zanidatamab:
Biliary Tract Cancer
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Others In May, the company rejected an acquisition proposal from All Blue Falcons.
2022 Plans/Strategy In April, the company secured an unsolicited, non-binding proposal from All Blue Falcons FZE and its affiliates to purchase the company for US $10.50 per share in cash.
2021 Others In December, the company announced new clinical data for the HER2-targeted bispecific antibody, zanidatamab, in heavily pretreated HER2-positive breast cancer.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Zymeworks Inc Seagen Inc Puma Biotechnology Inc MacroGenics Inc AngioChem Inc
Headquarters Canada United States of America United States of America United States of America Canada
City Vancouver Bothell Los Angeles Rockville Westmount
State/Province British Columbia Washington California Maryland Quebec
No. of Employees 327 2,675 196 427 -
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Kenneth Galbraith Chairman; Chief Executive Officer Executive Board 2022 -
Neil Klompas Chief Financial Officer; Chief Operating Officer Senior Management 2022 -
Kathryn O’Driscoll Chief People Officer Senior Management 2019 57
Neil Josephson, M.D. Chief Medical Officer Senior Management 2021 -
Anthony Polverino, Ph.D. Executive Vice President - Early Development; Chief Scientific Officer Senior Management 2018 58
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer